Fred Lublin, MD

• 2017
  Clifford Goldsmith Award
  

• 2017
  Honorary Member of the French Society of Neurology
  

• 2013
  Award of Appreciation for Outstanding Academic Teaching
  

• 2001
  Attending of the Year Award
  

• 2000
  Chairman, Research Programs Advisory Committee
  

• 1999
  McEwan Visiting Professorship & Lecture in Neurology
  

• 1999
  Hope Award
  

• 1996
  Milestone Award
  

Neuroimmunology

Basic and translational neuroimmunology

Multiple Sclerosis

Clinical trials in MS and other demyelination disorders

Katz Sand I MD, Fabian M MD, Lublin F MD. Open-label, add-on trial of cetirizine for neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2018; 5: e441.

Klineova S, Lublin FD, Mormina E, Buyukturkoglu K, Podranski K, Heinig MM, Pontillo G, Russo C, Tedeschi E, Russo CV, Costabile T, Lanzillo R, Harel A, Klineova S, Miller A, Brunetti A, Morra VB, Lublin F, Inglese M. Clinical Course of Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine 2018 Sep; 8(9).

Klineova S, Farber R, Friedman J, Farrell C, Lublin FD, Krieger S, Lublin FD, Inglese M, Lublin F, Inglese M, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Objective and subjective measures of dalfampridine efficacy in clinical practice. Multiple Sclerosis Journal - Experimental, Translational and Clinical 2018; 4(3).

Petracca M, Sumowski J, Fabian M, Miller A, Lublin F, Inglese M. Looking into cognitive impairment in primary-progressive multiple sclerosis. European Journal of Neurology 2018 01; 25(1).

Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Multiple Sclerosis Journal - Experimental, Translational and Clinical 2018; 4(1).

Connick P, De Angelis F, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. BMJ Open 2018 Aug; 8(8).

Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Multiple Sclerosis Journal - Experimental, Translational and Clinical 2018; 4(1).

Harel A, Sperling D, Petracca M, Ntranos A, Katz-Sand I, Krieger S, Lublin F, Wang Z, Liu Y, Inglese M, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J. Brain microstructural injury occurs in patients with RRMS despite 'no evidence of disease activity'. Journal of Neurology, Neurosurgery, and Psychiatry 2018 Sep; 89(9).

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BM, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet: Neurology 2018 Feb; 17(2).

Miller DH, Lublin FD, Sormani MP, Kappos L, Yaldizli Ö, Freedman MS, Cree BA, Weiner HL, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CA, Li B, Putzki N, Merschhemke M, Häring DA, Wolinsky JS, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BM, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study. Annals of Clinical and Translational Neurology 2018 03; 5(3).

Cocozza S, Petracca M, Mormina E, Buyukturkoglu K, Podranski K, Heinig MM, Pontillo G, Russo C, Tedeschi E, Russo CV, Costabile T, Lanzillo R, Harel A, Klineova S, Miller A, Brunetti A, Morra VB, Lublin F, Inglese M, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Cerebellar lobule atrophy and disability in progressive MS. Journal of Neurology, Neurosurgery, and Psychiatry 2017 Dec; 88(12).

Goodman AD, Bethoux F, Brown TR, Schapiro RT, Cohen R, Marinucci LN, Henney HR, Blight AR, Hartung HP, Montalban X, Uitdehaag BM, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CA, Li B, Putzki N, Merschhemke M, Häring DA, Wolinsky JS, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BM, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials. Multiple Sclerosis (Houndmills, Basingstoke, England) 2015 Jan;.

Weisfeld-Adams JD, Katz Sand IB, Honce JM, Lublin FD, Lublin F, Inglese M, Henney HR, Blight AR, Hartung HP, Montalban X, Uitdehaag BM, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CA, Li B, Putzki N, Merschhemke M, Häring DA, Wolinsky JS. Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis. Brain: a Journal of Neurology 2015 Mar; 138(Pt 3).

Datta S, Staewen TD, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS, Narayana PA, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BM, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Regional gray matter atrophy in relapsing remitting multiple sclerosis: baseline analysis of multi-center data. Multiple Sclerosis and Related Disorders 2015 Mar; 4(2).

Pardini M, Petracca M, Harel A, Fleysher L, Oesingmann N, Bommarito G, Fabian M, Chard D, Lublin F, Inglese M, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. The relationship between cortical lesions and periventricular NAWM abnormalities suggests a shared mechanism of injury in primary-progressive MS. NeuroImage. Clinical 2017; 16.

Poretto V, Petracca M, Saiote C, Mormina E, Howard J, Miller A, Lublin FD, Inglese M, Dive-Pouletty C, Bégo-Le-Bagousse G, Kappos L, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. A composite measure to explore visual disability in primary progressive multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical 2017; 3(2).

Vidaurre OG, Haines JD, Katz Sand I, Adula KP, Huynh JL, McGraw CA, Zhang F, Varghese M, Sotirchos E, Bhargava P, Bandaru VV, Pasinetti G, Zhang W, Inglese M, Calabresi PA, Wu G, Miller AE, Haughey NJ, Lublin FD, Casaccia P, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BM, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. Brain : a Journal of Neurology 2014 Aug; 137(Pt 8).

Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD, Miller A, Brunetti A, Morra VB, Lublin F, Inglese M. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet. Neurology 2014 Jun; 13(6).

Oynhausen S, Alcauskas M, Hannigan C, Bencosme Y, Müller M, Lublin F, Krieger S, Weiner HL, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CA, Li B, Putzki N, Merschhemke M, Häring DA, Wolinsky JS, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BM, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Emergency medical care of multiple sclerosis patients: primary data from the mount sinai resource utilization in multiple sclerosis project. Journal of Clinical Neurology (Seoul, Korea) 2014 Jul; 10(3).

Lublin FD, Haines JD, Katz Sand I, Adula KP, Huynh JL, McGraw CA, Zhang F, Varghese M, Sotirchos E, Bhargava P, Bandaru VV, Pasinetti G, Zhang W, Inglese M, Calabresi PA, Wu G, Miller AE, Haughey NJ, Lublin FD, Casaccia P, Weir CJ, Stallard N, Chandran S, Chataway J. New multiple sclerosis phenotypic classification. European Neurology 2014; 72 Suppl 1.

Pandey KS, Lublin FD, Miller AE, Krieger SC, Wolinsky JS, Narayana PA, Hartung HP, Montalban X, Uitdehaag BM, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CA, Li B, Putzki N, Merschhemke M, Häring DA, Wolinsky JS, Weir CJ, Stallard N, Chandran S, Chataway J. Clinical Course in Multiple Sclerosis Patients Presenting with a History of Progressive Disease. Multiple Sclerosis and Related Disorders 2014;(3): 67-71.

Lublin FD, Bowen J, Huddlestone J, Kremenchutzky J, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD, Calabresi PA, Wu G, Miller AE, Haughey NJ, Lublin FD, Casaccia P. Human Placenta-Derived Cells (PDA-001) for the Treatment of Adults with Multiple Sclerosis: A Randomized, Placebo-Controlled, Multiple-Dose Study. Multiple Sclerosis and Related Disorders 2014 September;.

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014 Jul; 83(3).

Lublin FD, Cutter G, Giovannoni G, Pace a, Müller M, Lublin F, Krieger S, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD, Calabresi PA, Wu G, Miller AE, Haughey NJ, Lublin FD, Casaccia P. Natalizumab Reduces Relapse Clinical Severity and Improves Relapse Recovery in MS. Multiple Sclerosis and Related Disorders 2014 September;.

Lublin FD, Bowen J, Huddlestone J, Kremenchutzky J, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. MS as a gateway disease. Journal of the neurological sciences 2013 Oct; 333(1-2).

O'Connor PW, Lublin FD, Wolinsky JS, Confavreux C, Comi G, Freedman MS, Olsson TP, Miller AE, Dive-Pouletty C, Bégo-Le-Bagousse G, Kappos L, Cappiello L, von Rosenstiel P, Lublin FD, Calabresi PA, Wu G, Miller AE, Haughey NJ, Lublin FD, Casaccia P. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. Journal of Neurology 2013 Oct; 260(10).

Narayana PA, Govindarajan KA, Goel P, Datta S, Lincoln JA, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center study. NeuroImage. Clinical 2012; 2.

Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, Salter AR, Gustafson T, Wolinsky JS, Kappos L, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology 2013 Mar; 73(3).

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology 2011 Feb; 69(2).

Lublin FD, Bowen JD, Huddlestone J, Kremenchutzky M, Carpenter A, Corboy JR, Freedman MS, Krupp L, Paulo C, Hariri RJ, Fischkoff SA. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. Multiple Sclerosis and Related Disorders 2014 Nov; 3(6).